© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 4, 293-298,
February 15, 1995
© 1995 Oxford University Press
Inhibition of Angiogenesis and Murine Hemangioma Growth by Batimastat, a Synthetic Inhibitor of Matrix Metalloproteinases
1Mario Negri Institute for Pharmacological Research Bergamo, Italy
2Istituto di Anatomia Patologica Veterinaria e Patologia Aviare, Università degli Studi Milan, Italy
3British Biotech Pharmaceuticals Ltd. Oxford, England
Correspondence to. Giulia Taraboletti, Ph.D., Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11, 24125 Bergamo, Italy.
Background: The importance of matrix metalloproteinases in angiogenesis, tumor growth, and metastasis is well known. However, little is known about the role of matrix metalloproteinases in the formation of hemangiomas and about the possible therapeutic use of matrix metalloproteinase inhibitors in aggressive vascular tumors. Purpose: To study the role of matrix metalloproteinase in vascular tumors, we tested the antineoplastic activity of a synthetic inhibitor of matrix metalloproteinases, batimastat, on an experimental model of hemangioma, formed by murine endothelioma cells transformed by polyoma middle-T on-cogene (eEnd.l). Methods: The effect of batimastat was studied in vivo on the formation of hemorrhaging, cavernous hemangiomas by eEnd.l endothelioma cells injected subcutaneously in nude mice and on the angiogenic response induced by an endothelioma cell supernatant embedded in a pellet of reconstituted basement membrane (Matrigel). The effect of batimastat was investigated in vitro on endothelial cell proliferation, motility, and invasion of a layer of Matrigel. Results: Daily treatment with batimastat (30, 3, and 0.3 mg/kg at the site of eEnd.l cell injection) inhibited tumor growth, with increased doubling time. The car-boxamide derivative of batimastat, BB-374, a poor inhibitor of matrix met-alloproteinase activity, was less active in reducing hemangioma growth. His-tologic analysis of treated tumors indicated a reduction in the size of blood-filled spaces and in hemorrhage. Batimastat also inhibited the angio-genic response induced by cultured eEnd.l endothelioma cell supernatant embedded in a pellet of Matrigel. Batimastat significantly inhibited endo-thelial cell invasion in vitro through a layer of Matrigel, but it showed no direct cytotoxic activity. Conclusions: Batimastat reduces in vivo growth of experimental hemangiomas, most probably by blocking endothelial cell recruitment by the transformed cells or by interfering with cell organization in vascular structures. Implications: These results confirm the importance of matrix metalloproteinase in endothelial cell recruitment that occurs in angiogenesis and in the formation of vascular tumors and suggest a therapeutic potential for synthetic matrix metalloproteinase inhibitors. [J Natl Cancer Inst 87: 293-298, 1995]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Gordillo, D. Onat, M. Stockinger, S. Roy, M. Atalay, F. M. Beck, and C. K. Sen A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation Am J Physiol Cell Physiol, October 1, 2004; 287(4): C866 - C873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Zarbin Current Concepts in the Pathogenesis of Age-Related Macular Degeneration Arch Ophthalmol, April 1, 2004; 122(4): 598 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Belotti, P. Paganoni, L. Manenti, A. Garofalo, S. Marchini, G. Taraboletti, and R. Giavazzi Matrix Metalloproteinases (MMP9 and MMP2) Induce the Release of Vascular Endothelial Growth Factor (VEGF) by Ovarian Carcinoma Cells: Implications for Ascites Formation Cancer Res., September 1, 2003; 63(17): 5224 - 5229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Trexler, K. Briknarova, M. Gehrmann, M. Llinas, and L. Patthy Peptide Ligands for the Fibronectin Type II Modules of Matrix Metalloproteinase 2 (MMP-2) J. Biol. Chem., March 28, 2003; 278(14): 12241 - 12246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Miller, W. Gradishar, L. Schuchter, J. A. Sparano, M. Cobleigh, N. Robert, H. Rasmussen, and G. W. Sledge A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer Ann. Onc., August 1, 2002; 13(8): 1220 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Luo, B. Mari, I. Stoll, and P. Anglard Alternative Splicing and Promoter Usage Generates an Intracellular Stromelysin 3 Isoform Directly Translated as an Active Matrix Metalloproteinase J. Biol. Chem., July 5, 2002; 277(28): 25527 - 25536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.S. Brock and S.M. Lee Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Eur. Respir. J., March 1, 2002; 19(3): 557 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cianfrocca, T. P. Cooley, J. Y. Lee, M. A. Rudek, D. T. Scadden, L. Ratner, J. M. Pluda, W. D. Figg, S. E. Krown, and B. J. Dezube Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study J. Clin. Oncol., January 1, 2002; 20(1): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hoekstra, F.A.L.M. Eskens, and J. Verweij Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives Oncologist, October 1, 2001; 6(5): 415 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E.J.M. Creemers, J. P.M. Cleutjens, J. F.M. Smits, and M. J.A.P. Daemen Matrix Metalloproteinase Inhibition After Myocardial Infarction: A New Approach to Prevent Heart Failure? Circ. Res., August 3, 2001; 89(3): 201 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Pepper Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1104 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hidalgo and S. G. Eckhardt Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy J Natl Cancer Inst, February 7, 2001; 93(3): 178 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model PNAS, April 11, 2000; 97(8): 3884 - 3889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sunami, N. Tsuno, T. Osada, S. Saito, J. Kitayama, S. Tomozawa, T. Tsuruo, Y. Shibata, T. Muto, and H. Nagawa MMP-1 is a Prognostic Marker for Hematogenous Metastasis of Colorectal Cancer Oncologist, April 1, 2000; 5(2): 108 - 114. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. P. Pereda, M. F. Ledda, V. Goldberg, A. Chervín, G. Carrizo, H. Molina, A. Müller, U. Renner, O. Podhajcer, E. Arzt, et al. High Levels of Matrix Metalloproteinases Regulate Proliferation and Hormone Secretion in Pituitary Cells J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 263 - 269. [Abstract] [Full Text]
|
|
|
|
|
|
C. Gatto, M. Rieppi, P. Borsotti, S. Innocenti, R. Ceruti, T. Drudis, E. Scanziani, A. M. Casazza, G. Taraboletti, and R. Giavazzi BAY 12-9566, A Novel Inhibitor of Matrix Metalloproteinases with Antiangiogenic Activity Clin. Cancer Res., November 1, 1999; 5(11): 3603 - 3607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Price, Q. Shi, D. Morris, M. E. Wilcox, P. M. A. Brasher, N. B. Rewcastle, D. Shalinsky, H. Zou, K. Appelt, R. N. Johnston, et al. Marked Inhibition of Tumor Growth in a Malignant Glioma Tumor Model by a Novel Synthetic Matrix MetalloproteinaseInhibitor AG3340 Clin. Cancer Res., April 1, 1999; 5(4): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Macaulay, K. J. O'Byrne, M. P. Saunders, J. P. Braybrooke, L. Long, F. Gleeson, C. S. Mason, A. L. Harris, P. Brown, and D. C. Talbot Phase I Study of Intrapleural Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in the Treatment of Malignant Pleural Effusions Clin. Cancer Res., March 1, 1999; 5(3): 513 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Cox, W P Steward, and K J O'Byrne The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer Thorax, February 1, 1999; 54(2): 169 - 179. [Full Text]
|
|
|
|
 |
|
 A Puyraimond, J. Weitzman, E Babiole, and S Menashi Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells J. Cell Sci., January 5, 1999; 112(9): 1283 - 1290. [Abstract] [PDF]
|
|
|
|
|
|
H. Wang and J. A. Keiser Vascular Endothelial Growth Factor Upregulates the Expression of Matrix Metalloproteinases in Vascular Smooth Muscle Cells : Role of flt-1 Circ. Res., October 19, 1998; 83(8): 832 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Mari, I. C. Anderson, S. E. Mari, Y. Ning, Y. Lutz, L. Kobzik, and M. A. Shipp Stromelysin-3 Is Induced in Tumor/Stroma Cocultures and Inactivated via a Tumor-specific and Basic Fibroblast Growth Factor-dependent Mechanism J. Biol. Chem., January 2, 1998; 273(1): 618 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Sabapathy, M. S. Pepper, F. Kiefer, U. Mohle-Steinlein, F. Tacchini-Cottier, I. Fetka, G. Breier, W. Risau, P. Carmeliet, R. Montesano, et al. Polyoma Middle T-induced Vascular Tumor Formation: The Role of the Plasminogen Activator/Plasmin System J. Cell Biol., May 19, 1997; 137(4): 953 - 963. [Abstract] [Full Text] [PDF]
|
|